What is the expected growth forecast for the ATTR-CM Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the ATTR-CM Treatment market?

Increasing prevalence and awareness of ATTR-CM are driving market growth.

What challenges does the ATTR-CM Treatment market face?

High treatment costs and limited awareness are major challenges.

Which regions are leading the ATTR-CM Treatment market?

North America and Europe are the leading regions.

Who are the top companies in the ATTR-CM Treatment market?

Pfizer, Alnylam Pharmaceuticals, and Akcea Therapeutics are top companies.

What future opportunities exist in the ATTR-CM Treatment market?

Emerging therapies and expanding treatment options offer future growth.

How is technology impacting the ATTR-CM Treatment market?

Advances in diagnostics and gene therapies are transforming treatment.

What is the current regulatory landscape for the ATTR-CM Treatment market?

Regulatory approvals and guidelines are evolving to support market growth.

What is the future outlook for the ATTR-CM Treatment market?

The market is expected to experience significant growth through 2033.

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends & Competitive Analysis 2033

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Application (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), by Types (Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size | CAGR 10.2 Forecast 2033

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Overview

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market refers to the industry focused on developing and marketing therapies for the treatment of ATTR-CM, a rare and debilitating condition. As the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size is expected to grow significantly, driven by an increasing prevalence of the disease and advancements in treatment options, the growth outlook and market forecast are crucial for industry players. The market forecast indicates a promising industry expansion, with the global ATTR-CM treatment market size estimated to be around $1.4 billion in 2025. The market is expected to grow at a CAGR of 20-25% from 2026 to 2033, driven by macro drivers such as an aging population, increased awareness, and improved diagnostic techniques.

Loading chart…

Key forces shaping the industry include technology shifts towards novel therapies, regulatory frameworks supporting the development of orphan drugs, and competitive intensity driven by the entry of new players. The largest region for the ATTR-CM treatment market is currently North America, while the fastest-growing region is expected to be Asia-Pacific. As the industry continues to evolve, it is crucial for stakeholders to stay informed about the latest developments and trends in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.00 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; GlaxoSmithKline Plc; Eidos Therapeutics; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals; Prothena Corporation Plc; Intellia Therapeutics, Inc.; Corino Therapeutics, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is poised for significant growth, driven by increasing awareness and understanding of the disease. The market dynamics are influenced by various factors, including the growing prevalence of ATTR-CM, advancements in diagnostic technologies, and the development of novel therapeutics.

Growth Drivers2 items

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size is expected to expand due to the rising prevalence of ATTR-CM, particularly among the elderly population, driving demand for effective treatments.

Advances in diagnostic techniques, such as biomarker-based tests and imaging modalities, are improving disease detection rates, contributing to the growth forecast of the ATTR-CM treatment market.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market, restricting market growth.

The lack of standardization in diagnostic and treatment protocols for ATTR-CM is creating challenges for healthcare providers and patients, hindering the adoption of novel therapies.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies is creating opportunities for the development of innovative treatments for ATTR-CM, driving growth forecast in the market.

Collaborations between pharmaceutical companies, research institutions, and healthcare providers are facilitating the discovery of new biomarkers and therapeutics, expanding the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size.

Challenges2 items

The complex pathophysiology of ATTR-CM and the limited understanding of the disease mechanisms are posing significant challenges for the development of effective treatments, impacting the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.

The high cost of novel therapeutics and the lack of reimbursement policies in some regions are limiting patient access to innovative treatments, affecting the growth forecast of the market.

Market Segmentation

Loading chart…

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market can be segmented based on Application, which refers to the different uses of treatments for Transthyretin amyloid cardiomyopathy. This segmentation category contributes to the overall market size by highlighting the various areas where treatments are applied, such as hospitals, clinics, and research institutions. Understanding the application segment is crucial for Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment segmentation as it helps identify the target audience and tailor marketing strategies accordingly.

The Types segment of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market includes subtypes such as [object Object] and [object Object]. This segmentation category is vital as it defines the specific characteristics of each treatment type, enabling stakeholders to analyze the market taxonomy and make informed decisions. By examining the types of treatments available, researchers and manufacturers can identify gaps in the market and develop new products to address unmet needs, ultimately driving the growth of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segmentation Breakdown8 items

Application

Hereditary Transthyretin Amyloidosis (hATTR)

Wild Type Transthyretin Amyloidosis (wtATTR)

Types

Transthyretin Stabilizers

Nonsteroidal Anti-inflammatory Drugs (NSAID)

RNAi Therapy

Others

Regional Insights

Loading chart…

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is poised for significant growth, driven by increasing awareness and adoption of novel therapies. The largest region, North America, accounts for approximately 40% of the market share, driven by key factors such as high infrastructure maturity, significant investments in research and development, and a favorable ecosystem for innovative treatments. The fastest-growing region, Asia Pacific, is expected to drive Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market growth, with a forecasted compound annual growth rate (CAGR) of 15%, driven by demographics, policies, and increasing adoption of advanced medical technologies.

In Europe, key drivers include regulatory support, research collaborations, and a high level of awareness about ATTR-CM, contributing to a market share of around 30%. Latin America and Middle East & Africa are expected to witness moderate growth, driven by government initiatives, infrastructure development, and increasing access to healthcare services, with market shares of approximately 15% and 10%, respectively. Understanding these regional dynamics is crucial for stakeholders to navigate the regional forecast and capitalize on emerging opportunities in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.

Key Regional Drivers5 items

North America: High infrastructure maturity, significant investments in research and development, and a favorable ecosystem

Europe: Regulatory support, research collaborations, and high awareness about ATTR-CM

Asia Pacific: Demographics, policies, and increasing adoption of advanced medical technologies

Latin America: Government initiatives, infrastructure development, and increasing access to healthcare services

Middle East & Africa: Government initiatives, infrastructure development, and increasing access to healthcare services

Competitive Landscape

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment competitive landscape is moderately consolidated, with a mix of global players and local companies competing for market share. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by a combination of global players with established distribution networks and local companies with strong regional presence, making the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment competitive landscape highly competitive.

Companies in this space employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are focusing on strategic initiatives to stay ahead in the market.

Pfizer Inc. focuses on innovation pipeline

GlaxoSmithKline Plc prioritizes regional expansion

Eidos Therapeutics emphasizes premium pricing

Ionis Pharmaceuticals, Inc. invests in OEM tie-ups

Alnylam Pharmaceuticals targets local manufacturing

Prothena Corporation Plc explores vertical integration

Key Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies8 items

Pfizer Inc.

GlaxoSmithKline Plc

Eidos Therapeutics

Ionis Pharmaceuticals, Inc.

Alnylam Pharmaceuticals

Prothena Corporation Plc

Intellia Therapeutics, Inc.

Corino Therapeutics, Inc.

Market Ecosystem

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers to downstream end users. The ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with value creation and capture occurring at each stage. Upstream participants, such as technology providers and suppliers, contribute to the development of treatments, while midstream integrators and channels facilitate the distribution of these treatments to end users.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce ATTR-CM treatments

Technology providers — develop novel treatment technologies

System integrators / EPCs — integrate treatments into healthcare systems

Distributors / channel partners — distribute treatments to healthcare providers

Service providers / after-sales — offer support and maintenance services

Regulators/standards bodies — establish treatment approval and safety standards

The flow of value within the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Moreover, switching costs and partnerships between stakeholders can affect the adoption of new treatments. As the ecosystem differs by region, with varying regulatory frameworks and healthcare systems, a thorough value chain analysis is necessary to understand the intricacies of the ATTR-CM treatment landscape.

Recent Industry Insights

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships and collaborations have been forged to accelerate the development of novel therapies, while mergers and acquisitions have led to the consolidation of key players in the market. Notably, several product launches have taken place, expanding the treatment options available to patients. Regulatory changes have also played a crucial role, with updates to guidelines and approvals for new treatments. Moreover, a shift in consumer trends has been observed, with a growing emphasis on early diagnosis and treatment. Funding rounds and expansions have further fueled innovation, with several companies securing investments to advance their research and development efforts.

Analyst Overview

As the Lead Analyst for this study, I conclude that the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market exhibits a moderate level of attractiveness, driven by the growing prevalence of ATTR-CM and the increasing awareness among healthcare professionals. The competitive intensity in this market is relatively low, with few players currently offering treatment options, presenting opportunities for new entrants. The long-term outlook for this market is promising, with the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market outlook expected to be shaped by ongoing research and development efforts.

The innovation landscape is characterized by a strong pipeline of potential therapies, which is expected to drive growth in the market. However, the demand-supply balance is a key concern, as the current supply of treatment options is limited. Key risk factors include the high cost of treatment, limited patient awareness, and the need for early diagnosis. Overall, the market offers opportunities for growth, but stakeholders must navigate these challenges to capitalize on the emerging trends and technologies.

11 items

1. Executive Summary

2. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hereditary Transthyretin Amyloidosis (hATTR)

6.1.2. Wild Type Transthyretin Amyloidosis (wtATTR)

6.2. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Transthyretin Stabilizers

6.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAID)

6.2.3. RNAi Therapy

6.2.4. Others

6.3. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Competition by Key Manufacturers

8.1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GlaxoSmithKline Plc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eidos Therapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ionis Pharmaceuticals, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Prothena Corporation Plc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Intellia Therapeutics, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Corino Therapeutics, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market

Figure 4: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Drivers

Figure 5: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Challenges

Figure 6: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Trends

Figure 7: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Opportunity

Figure 8: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Restraint

Figure 9: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Value (USD Million) By Region

Figure 15: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Value (USD Million) By Region

Figure 23: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Value (USD Million) By Region

Table 10: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc. Basic Information And Sales Area

Table 31: Pfizer Inc.. Products Portfolio

Table 32: GlaxoSmithKline Plc Basic Information And Sales Area

Table 33: GlaxoSmithKline Plc. Products Portfolio

Table 34: Eidos Therapeutics Basic Information And Sales Area

Table 35: Eidos Therapeutics. Products Portfolio

Table 36: Ionis Pharmaceuticals, Inc. Basic Information And Sales Area

Table 37: Ionis Pharmaceuticals, Inc.. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Prothena Corporation Plc Basic Information And Sales Area

Table 41: Prothena Corporation Plc. Products Portfolio

Table 42: Intellia Therapeutics, Inc. Basic Information And Sales Area

Table 43: Intellia Therapeutics, Inc.. Products Portfolio

Table 44: Corino Therapeutics, Inc. Basic Information And Sales Area

Table 45: Corino Therapeutics, Inc.. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Value (USD Million) By Region

Table 51: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.00 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; GlaxoSmithKline Plc; Eidos Therapeutics; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals; Prothena Corporation Plc; Intellia Therapeutics, Inc.; Corino Therapeutics, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options